Financial venture capital (VC) and corporate VC are among the most important source of funding of small companies in healthcare industry in Europe and USA. Countries in Asia are now catching up, especially in the greater China region, where R D expenditure was increasing tremendously in the last decade. In this thesis, we analyzed the ecosystem of venture capital as well as pharma-backed corporate VC investment in the greater China region compared to the US and Europe. We tried to identify the criteria of corporate VCs for making investment decisions by analyzing the investment portfolio from public available information and conducting interviews with investors from venture arm of big pharmaceutical companies and financial venture capitalists who had experiences in both US/EU and the greater China region. This thesis highlights the acceleration of corporate equity investing in the greater China region. The findings are consistent with data from Europe and USA where a recent analysis confirmed the critically important contribution of CVC and direct corporate investing for start-up and emerging biotech companies over the past 15 years, and importantly, the correlation between corporate investor involvement and successful ‘exit’ outcomes. As the Covid-19 pandemic hit worldwide, many VCs had become conservative in their investment. It is an appropriate timing to evaluate if the greater China region has more opportunities to be a preferred location for corporate investing in Asia and enable the translation of broader footprint of innovative science into new medicines in the next five years.